CTMX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
1.7M
+19.0%
1.4M
-86.2%
10.3M
+1447.2%
663.0K
-88.9%
6.0M
Cost of Revenue
0
0
0
0
0
Gross Profit
1.7M
+19.0%
1.4M
-86.2%
10.3M
+1447.2%
663.0K
-88.9%
6.0M
Operating Expenses
25.2M
-0.0%
25.2M
-15.8%
29.9M
+4.7%
28.6M
+31.6%
21.7M
R&D
16.5M
-6.4%
17.6M
-8.5%
19.2M
-9.4%
21.2M
+38.8%
15.3M
SG&A
8.7M
+14.6%
7.6M
-28.9%
10.7M
+45.3%
7.4M
+14.5%
6.4M
Operating Income
-23502000
+1.2%
-23781000
-20.9%
-19672000
+29.6%
-27932000
-77.1%
-15768000
EBITDA
-23087000
+2.7%
-23734000
-22.2%
-19421000
+29.2%
-27422000
-75.4%
-15634000
Net Income
-19998000
+3.2%
-20666000
-13.3%
-18248000
+31.2%
-26510000
-86.3%
-14229000
EPS (Basic)
$-0.09
+0.0%
$-0.09
+10.0%
$-0.10
+41.2%
$-0.17
-88.9%
$-0.09
EPS (Diluted)
$-0.09
+0.0%
$-0.09
+10.0%
$-0.10
+41.2%
$-0.17
-88.9%
$-0.09
Shares (Diluted)
219.1M
+0.1%
218.9M
+23.5%
177.3M
+4.0%
170.5M
+3.3%
165.0M
CytomX Therapeutics (CTMX) — Financials